RAD51 expression and prognostic impact in patients with stomach adenocarcinoma
PeerJ · 11.04.2025 · 13 · e19179
DOI: 10.7717/peerj.19179 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 11.04.2025. Verfasst von Baiyu Jian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Qiqihar Medical University, Qiqihar, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Rad51 Recombinase, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The program of the National Science Foundation of China, The Natural Science Foundation of Heilongjiang Province for Excellent Young Scholar, Qiqihar Municipal Bureau of Science and Technology.
Abstract (Originalsprache)
Background
Stomach adenocarcinoma (STAD) is the most common gastrointestinal cancer. A clear diagnosis and molecular targeted therapy have important implications for prolonging survival of patients. RAD51 is the central catalyst of homologous recombination that plays important role in maintaining genomic integrity. However, the clinical significance of RAD51 expression in STAD patients remains unclear. This study aimed to assess the association of RAD51 expression with clinicopathological characteristics and patient outcomes.
Methods
In this study, RAD51 mRNA expression in STAD patients was assessed using the UALCAN and GEPIA databases. The diagnostic value of RAD51 was evaluated by analyzing the ROC curve (data from the The Cancer Genome Atlas (TCGA) database). The protein expression level of RAD51 in STAD patients and its relationship with clinicopathological characteristics and prognosis were evaluated by immunohistochemistry. Co-expression analysis of RAD51 in STAD was performed by Coexpedia and Gene Expression Profiling Interactive Analysis (GEPIA) databases. The associations of RAD51 and its co-expression genes with immune infiltrates were analyzed in TIMER database.
Results
Our bioinformatic analysis revealed that RAD51 demonstrates elevated expression in STAD. The ROC curve analysis yielded an AUC value of 0.9366 (95% CI [0.9075–0.9658]), confirming its potential as a biomarker for STAD. Immunohistochemical assessments validated the up-regulation of RAD51 in STAD, highlighting its significant correlation with TNM stage and T stage, but not with age, sex, grade, N stage, M stage, or P53 expression. Patients exhibiting high RAD51 expression exhibited significantly reduced overall survival. Multivariate analysis identified RAD51 expression may serve as an independent prognostic biomarker of poor prognosis in patients with STAD. Additionally, our bioinformatic analysis identified eight RAD51 co-expression genes (AURKA, CKS1B, NUSAP1, PFDN4, CCNE1, CDCA4, KIF4A, and MCM10) in STAD. Moreover, we discovered that RAD51 and its main co-expressed genes were significantly negatively associated with most or all immune cell infiltration.
Conclusions
RAD51 overexpression was related to disease progression and poor prognosis, as well as infiltration of immune cells in gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qiqihar Medical University, Qiqihar, China.
- Heilongjiang University of Chinese Medicine, Harbin, China.
Förderung
- The program of the National Science Foundation of China
- The Natural Science Foundation of Heilongjiang Province for Excellent Young Scholar
- Qiqihar Municipal Bureau of Science and Technology
- The Program of Qiqihar Academy of Medical Sciences
- The Scientific Research Fund of Heilongjiang Provincial Education Department
Zitieren
APA
Jian, B., Zhang, H., Fan, L., Li, Y., Wu, N., Wang, N., Li, L., Li, X., Ge, P., Niu, Y., & Liu, J. (2025). RAD51 expression and prognostic impact in patients with stomach adenocarcinoma. PeerJ, 13, e19179. https://doi.org/10.7717/peerj.19179
Vancouver
Jian B, Zhang H, Fan L, Li Y, Wu N, Wang N, et al. RAD51 expression and prognostic impact in patients with stomach adenocarcinoma. PeerJ. 2025;13:e19179. doi:10.7717/peerj.19179
BibTeX
@article{Jian2025,
author = {Jian, Baiyu and Zhang, Hao and Fan, Li and Li, Yang and Wu, Nan and Wang, Ningning and Li, Lingmin and Li, Xueyan and Ge, Pengling and Niu, Yingcai and Liu, Jicheng},
title = {RAD51 expression and prognostic impact in patients with stomach adenocarcinoma},
journal = {PeerJ},
year = {2025},
volume = {13},
pages = {e19179},
doi = {10.7717/peerj.19179}
}
EUVIMED